Resistance modifying agents are active in some patients with hematological malignancy
- 1 April 1993
- journal article
- editorial
- Published by Elsevier in Leukemia Research
- Vol. 17 (4) , 295-298
- https://doi.org/10.1016/0145-2126(93)90015-d
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemiaBritish Journal of Cancer, 1992
- High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemiaBlood, 1992
- Multidrug Resistance in Acute Myeloid LeukemiaJNCI Journal of the National Cancer Institute, 1991
- Multidrug resistance (mdr) genes in human cancerBritish Journal of Cancer, 1991
- Reversal of multidrug resistanceCancer Treatment Reviews, 1990
- Expression of mdr1 and mdr3 Multidrug-resistance Genes in Human Acute and Chronic Leukemias and Association With Stimulation of Drug Accumulation by CyclosporineJNCI Journal of the National Cancer Institute, 1990
- Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissuesAnnals of Oncology, 1990
- P-glycoproteins in pathology: The multidrug resistance gene family in humansHuman Pathology, 1990
- Expression of the multidrug resistance gene in myeloid leukemiasLeukemia Research, 1989
- D‐verapamil and L‐verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitroInternational Journal of Cancer, 1988